Aptorum Group Limited to Present at the Infectious Disease Virtual Conference
2020年4月29日 - 9:00PM
ビジネスワイヤ(英語)
Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a
biopharmaceutical company focused on the development of novel
therapeutics to address global unmet medical needs, including
orphan diseases, infectious diseases and metabolic diseases, today
announced its participation at Maxim Group’s Infectious Disease
Virtual Conference on May 5, 2020, 10:00 a.m. ET. Aptorum Group’s
President and Executive Director Mr. Darren Lui will join a panel,
which entitled “Non-antibiotic Anti-infectives.” This panel is
scheduled for 10:30 a.m. ET to 12:00 p.m. ET. To RSVP for the
virtual conference, please click through:
https://m-vest.com/insights/blog/Infectious-Disease-Virtual-Conference-2020
To access the live presentation, please use the following
information:
Maxim Group’s Infectious Disease Virtual Conference Date:
Tuesday, May 5, 2020 Time: 10:00 AM Eastern Time (7:00 AM Pacific
Time)
Panel Session Title: Non-antibiotic Anti-infectives Date:
Tuesday, May 5, 2020 Time: 10:30 AM Eastern Time (7:30 AM Pacific
Time)
If you would like to book 1 on 1 investor meetings with Aptorum
Group, please make sure you are registered for the virtual event
here: http://m-vest.com/signup
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group's current drug pipeline
include indications in orphan diseases, infectious diseases and
metabolic diseases and a number of which are targeted to enter
clinical trial phases in 2020. Aptorum Group’s Dioscorea Opposita
Bioactive Nutraceutical Tablets, which is a dietary supplement for
women’s health during menopause and post-menopause cycles, are
currently being commercialized.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. As a result, the projections included
in such forward-looking statements are subject to change. Aptorum
Group assumes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200429005031/en/
Investors: Tel: +852 2117 6611 Email:
investor.relations@aptorumgroup.com
Media: Tel: + 852 2117 6611 Email: info@aptorumgroup.com
Aptorum (NASDAQ:APM)
過去 株価チャート
から 3 2024 まで 4 2024
Aptorum (NASDAQ:APM)
過去 株価チャート
から 4 2023 まで 4 2024